E6130 + Placebo

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Japanese Healthy Adult Male Participants

Conditions

Japanese Healthy Adult Male Participants

Trial Timeline

Sep 26, 2016 → Aug 17, 2017

About E6130 + Placebo

E6130 + Placebo is a phase 1 stage product being developed by Eisai for Japanese Healthy Adult Male Participants. The current trial status is completed. This product is registered under clinical trial identifier NCT02902978. Target conditions include Japanese Healthy Adult Male Participants.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (2)

NCT IDPhaseStatus
NCT03390647Phase 1Withdrawn
NCT02902978Phase 1Completed

Competing Products

20 competing products in Japanese Healthy Adult Male Participants

See all competitors
ProductCompanyStageHype Score
ASP3325 + PlaceboAstellas PharmaPhase 1
33
E2022 + E2022 + E2022 + E2022 + E2022EisaiPhase 1
33
AZD3293 + PlaceboAstraZenecaPhase 1
33
MEDI3250 + PlaceboAstraZenecaPhase 3
77
MEDI3250AstraZenecaPhase 3
77
Fostamatinib 100mg + Fostamatinib 200mgAstraZenecaPhase 1
33
NXL104 + CAZ104 + PlaceboPfizerPhase 1
32
CAIV-T + PlaceboPfizerPhase 1
32
ChimeriVax™-JE + JE-VAX®SanofiPhase 3
76
ChimeriVax™-JE + Japanese Encephalitis Inactivated Mouse Brain VaccineSanofiPhase 2
51
Live attenuated Japanese encephalitis virus + Live attenuated Japanese encephalitis virus + Live attenuated Japanese encephalitis virus + ChimeriVax™ diluent (Placebo)SanofiPhase 2
51
ChimeriVax™-JE vaccine + JE-VAX® vaccineSanofiPhase 2
51
Live attenuated Japanese encephalitis chimeric virus vaccine + Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine)SanofiPhase 3
76
IMOJEVSanofiPhase 3
76
Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) + Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) + Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) + Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)SanofiPhase 3
76
a live attenuated chimeric JE vaccineSanofiPre-clinical
22
Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus + Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus + Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virusSanofiPhase 3
76
IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine + IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccineSanofiApproved
84
JE-CV Vaccine + Varicella VaccineSanofiPhase 3
76
Live attenuated Japanese encephalitis virus; Yellow fever virus + Yellow fever virus; Live attenuated Japanese encephalitis virus + Live attenuated Japanese encephalitis virus; Yellow fever virus + Live attenuated Japanese encephalitis virus; Yellow fever virusSanofiPhase 2
51